Yao Neng Teo1, Yao Hao Teo1, Nicholas L Syn1, Celine Shuen Yin Yoong1, Alex Jia Yang Cheong1, Caitlin Fern Wee1, Yoke-Ching Lim1,2, Chi-Hang Lee1,2, Tiong-Cheng Yeo1,2, Ping Chai1,2, Raymond C C Wong1,2, Weiqin Lin1,2, Ching-Hui Sia3,4. 1. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. 2. Department of Cardiology, National University Heart Centre Singapore, 1E Kent Ridge Road, NUHS Tower Block Level 9, Singapore, 119228, Singapore. 3. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. ching_hui_sia@nuhs.edu.sg. 4. Department of Cardiology, National University Heart Centre Singapore, 1E Kent Ridge Road, NUHS Tower Block Level 9, Singapore, 119228, Singapore. ching_hui_sia@nuhs.edu.sg.
Abstract
BACKGROUND AND OBJECTIVE: In recent trials, sodium-glucose cotransporter 2 (SGLT2) inhibitors proved effective as treatment for heart failure. However, the relative efficacy of sacubitril/valsartan against SGLT2 inhibitor in patients with heart failure remains unknown. Hence, we performed a network meta-analysis to compare the effects of sacubitril/valsartan against SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure. METHODS: Four electronic databases (PubMed, Embase, Cochrane, SCOPUS) were searched for randomised-controlled trials (RCTs) published from 1st January 2000 to 25th September 2021. Two additional systematic reviews were conducted for RCTs of enalapril and valsartan to establish a common comparator arm. Frequentist network meta-analysis models were utilised to summarise the studies. RESULTS: Twenty-five RCTs were included, comprising a combined cohort of 47,275 patients. Network meta-analysis demonstrated that compared to SGLT2 inhibitors, sacubitril/valsartan achieved a larger hazard rate reduction in the composite of heart failure hospitalisation and cardiovascular death (hazard ratio [HR]: 0.86; 95% CI 0.75-0.98), cardiovascular death (HR: 0.78; 95% CI 0.65-0.94), and a larger mean change in systolic blood pressure at 8 or more months (weighted mean difference [WMD]: - 7.08 mmHg; 95% CI - 8.28 to - 5.89). There were no significant differences in treatment effects across heart failure hospitalisation, all-cause mortality, diastolic blood pressure at 12 weeks, and systolic blood pressure at 2-4 months. In patients with heart failure with reduced ejection fraction, sacubitril/valsartan achieved a 20% hazard rate reduction for cardiovascular death compared to SGLT2 inhibitors. CONCLUSIONS: In patients with heart failure, sacubitril/valsartan was demonstrated to be superior to SGLT2 inhibitors in the treatment effect for the composite of heart failure hospitalisation and cardiovascular death, cardiovascular death, and long-term blood pressure.
BACKGROUND AND OBJECTIVE: In recent trials, sodium-glucose cotransporter 2 (SGLT2) inhibitors proved effective as treatment for heart failure. However, the relative efficacy of sacubitril/valsartan against SGLT2 inhibitor in patients with heart failure remains unknown. Hence, we performed a network meta-analysis to compare the effects of sacubitril/valsartan against SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure. METHODS: Four electronic databases (PubMed, Embase, Cochrane, SCOPUS) were searched for randomised-controlled trials (RCTs) published from 1st January 2000 to 25th September 2021. Two additional systematic reviews were conducted for RCTs of enalapril and valsartan to establish a common comparator arm. Frequentist network meta-analysis models were utilised to summarise the studies. RESULTS: Twenty-five RCTs were included, comprising a combined cohort of 47,275 patients. Network meta-analysis demonstrated that compared to SGLT2 inhibitors, sacubitril/valsartan achieved a larger hazard rate reduction in the composite of heart failure hospitalisation and cardiovascular death (hazard ratio [HR]: 0.86; 95% CI 0.75-0.98), cardiovascular death (HR: 0.78; 95% CI 0.65-0.94), and a larger mean change in systolic blood pressure at 8 or more months (weighted mean difference [WMD]: - 7.08 mmHg; 95% CI - 8.28 to - 5.89). There were no significant differences in treatment effects across heart failure hospitalisation, all-cause mortality, diastolic blood pressure at 12 weeks, and systolic blood pressure at 2-4 months. In patients with heart failure with reduced ejection fraction, sacubitril/valsartan achieved a 20% hazard rate reduction for cardiovascular death compared to SGLT2 inhibitors. CONCLUSIONS: In patients with heart failure, sacubitril/valsartan was demonstrated to be superior to SGLT2 inhibitors in the treatment effect for the composite of heart failure hospitalisation and cardiovascular death, cardiovascular death, and long-term blood pressure.
Authors: Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos S Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake Journal: J Am Coll Cardiol Date: 2017-04-28 Impact factor: 24.094
Authors: Eric J Velazquez; David A Morrow; Adam D DeVore; Carol I Duffy; Andrew P Ambrosy; Kevin McCague; Ricardo Rocha; Eugene Braunwald Journal: N Engl J Med Date: 2018-11-11 Impact factor: 91.245
Authors: Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi Journal: N Engl J Med Date: 2015-09-17 Impact factor: 91.245
Authors: Theresa A McDonagh; Marco Metra; Marianna Adamo; Roy S Gardner; Andreas Baumbach; Michael Böhm; Haran Burri; Javed Butler; Jelena Čelutkienė; Ovidiu Chioncel; John G F Cleland; Andrew J S Coats; Maria G Crespo-Leiro; Dimitrios Farmakis; Martine Gilard; Stephane Heymans; Arno W Hoes; Tiny Jaarsma; Ewa A Jankowska; Mitja Lainscak; Carolyn S P Lam; Alexander R Lyon; John J V McMurray; Alexandre Mebazaa; Richard Mindham; Claudio Muneretto; Massimo Francesco Piepoli; Susanna Price; Giuseppe M C Rosano; Frank Ruschitzka; Anne Kathrine Skibelund Journal: Eur Heart J Date: 2021-09-21 Impact factor: 29.983
Authors: Scott D Solomon; John J V McMurray; Inder S Anand; Junbo Ge; Carolyn S P Lam; Aldo P Maggioni; Felipe Martinez; Milton Packer; Marc A Pfeffer; Burkert Pieske; Margaret M Redfield; Jean L Rouleau; Dirk J van Veldhuisen; Faiez Zannad; Michael R Zile; Akshay S Desai; Brian Claggett; Pardeep S Jhund; Sergey A Boytsov; Josep Comin-Colet; John Cleland; Hans-Dirk Düngen; Eva Goncalvesova; Tzvetana Katova; Jose F Kerr Saraiva; Małgorzata Lelonek; Bela Merkely; Michele Senni; Sanjiv J Shah; Jingmin Zhou; Adel R Rizkala; Jianjian Gong; Victor C Shi; Martin P Lefkowitz Journal: N Engl J Med Date: 2019-09-01 Impact factor: 91.245
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur Heart J Date: 2016-05-20 Impact factor: 29.983
Authors: David Fitchett; Bernard Zinman; Christoph Wanner; John M Lachin; Stefan Hantel; Afshin Salsali; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi Journal: Eur Heart J Date: 2016-01-26 Impact factor: 29.983